Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes

Conclusion:
With self-education or minimal training, participants accurately and precisely suspended, mixed, and delivered exenatide-containing microspheres using the dual-chamber pen with high ease-of-use scores. The dual-chamber pen was FDA-approved in February 2014.

Source: Journal of Diabetes Science and Technology - June 30, 2015 Category: Endocrinology Authors: LaRue, S., Malloy, J. Tags: Original Articles Source Type: research